

*Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.*



## **Lee's Pharmaceutical Holdings Limited**

**李氏大藥廠控股有限公司\***

*(incorporated in the Cayman Islands with limited liability)*

**(Stock Code: 950)**

### **SUPPLEMENTAL ANNOUNCEMENT REGARDING ANNUAL REPORT FOR THE YEAR ENDED 31 DECEMBER 2020**

Reference is made to the annual report of Lee's Pharmaceutical Holdings Limited (the "**Company**") for the year ended 31 December 2020 (the "**Annual Report**"). Unless the context requires otherwise, capitalised terms used in this announcement shall have the same meanings as defined in the Annual Report.

In addition to the information provided in the Annual Report, the Board would like to provide the following further information to the section headed "Share Option Scheme" under the Report of the Directors in the Annual Report pursuant to Rule 17.09 of the Listing Rules:

- (i) The total number of Shares available for issue under the New Share Option Scheme as at 31 December 2020 was 14,041,543 shares, representing approximately 2.4% of the Company's total number of issued shares as at the date of the Annual Report.
- (ii) Under the New Share Option Scheme, upon acceptance of the option, the grantee of an option must pay HK\$1 to the Company by way of consideration for the grant thereof.
- (iii) The 2002 Share Option Scheme and New Share Option Scheme shall be valid and effective for a period of 10 years from the date of adoption, i.e. 26 June 2002 and 10 May 2012 respectively. The 2002 Share Option Scheme expired on 9 May 2012. As at 31 December 2020, the remaining life of the New Share Option Scheme was approximately 1.4 years (i.e. until 9 May 2022).

\* *For identification purpose only*

The above additional information does not affect any other information contained in the Annual Report. Save as disclosed in this announcement, the remaining contents of the Annual Report remain unchanged.

By order of the Board  
**Lee's Pharmaceutical Holdings Limited**  
**Lee Siu Fong**  
*Chairman*

Hong Kong, 2 November 2021

*As at the date of this announcement, Ms. Lee Siu Fong (Chairman) and Ms. Leelalertsuphakun Wanee are executive directors of the Company; Dr. Li Xiaoyi is a non-executive director of the Company; Dr. Chan Yau Ching, Bob, Mr. Lam Yat Cheong and Dr. Tsim Wah Keung, Karl, are independent non-executive directors of the Company.*